Seeking Alpha

Dr. Paul Nunzio DeSantis, Pharm.D

 
ABOUT
Earned a Doctorate in Pharmacy (Pharm.D.) in 2010 and Pre-Pharmacy/B.S. in Molecular Biology in 2006. Over six years of direct experience in translational research in oncology investigating the molecular/cellular mechanisms of carcinogenesis focused on biomarker identification and validation working in a multi-disciplinary matrix environment across academia, contract research organizations and industry.

http://propthink.com/gileadreport/#

http://www.alphabiopharmaadvisers.com

http://www.linkedin.com/pub/dr-paul-nunzio-de-santis-pharm-d/31/994/b57

Analyst Tip Ranks: https://www.tipranks.com/experts/dr.-paul-nunzio-desantis%252C-pharm.d
SNAPSHOT
  • Description: Investment Consultant. Trading frequency: Daily
  • Interests: Commodities, Energy stocks, Foreign stocks, Forex, Gold, Options, Stocks - long, Stocks - short, Tech stocks
COMPANY
Alpha BioPharma Advisers The biopharma sector offers hedge funds one of the most attractive sources for generating alpha, however it also presents substantial volatility and risk. With numerous opportunities and catalysts each year from clinical trials, mergers and acquisitions, and licensing deals; if appropriately analyzed and ...More
BLOG
An Evidence-Driven Rebuttal To Morgan Stanley & Goldman Sachs Bearish Thesis On Gilead Sciences (GILD) Alpha Biopharma embarked on this meticulous project during the biotech selloff in March and April of 2014, a time at which GILD was in the headlines on a daily basis, assaulted on all fronts: from politicians on pricing; followed by two notable investment banks, Morgan Stanley & Goldman Sachs, who ...More
Book
An Evidence-Driven Rebuttal To Morgan Stanley & Goldman Sachs Bearish Thesis On Gilead Sciences (GILD) Alpha Biopharma embarked on this meticulous project during the biotech selloff in March and April of 2014, a time at which GILD was in the headlines on a daily basis, assaulted on all fronts: from politicians on pricing; followed by two notable investment banks, Morgan Stanley & Goldman Sachs, who ...More
LATEST STOCKTALK more »
PSivida Corp (PSDV): Imminent New Drug Approval, Steady News Flow, & Tethadur Partnership Raising... $PSDV http://seekingalpha.com/a/1fr4n Aug 12, 2014